Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 147,998,976
  • Shares Outstanding, K 5,685,708
  • Annual Sales, $ 63,627 M
  • Annual Income, $ 8,031 M
  • EBIT $ 18,723 M
  • EBITDA $ 25,736 M
  • 60-Month Beta 0.46
  • Price/Sales 2.30
  • Price/Cash Flow 5.89
  • Price/Book 1.57

Options Overview Details

View History
  • Implied Volatility 23.45% (-0.31%)
  • Historical Volatility 24.55%
  • IV Percentile 25%
  • IV Rank 15.34%
  • IV High 52.17% on 04/10/25
  • IV Low 18.25% on 08/18/25
  • Expected Move (DTE 4) 0.51 (1.96%)
  • Put/Call Vol Ratio 0.31
  • Today's Volume 225,341
  • Volume Avg (30-Day) 226,118
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 3,417,757
  • Open Int (30-Day) 3,603,907
  • Expected Range 25.52 to 26.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.63
  • Number of Estimates 4
  • High Estimate 0.77
  • Low Estimate 0.55
  • Prior Year 0.63
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.91 +8.87%
on 11/10/25
26.48 -1.68%
on 11/13/25
+1.42 (+5.77%)
since 11/05/25
3-Month
23.58 +10.39%
on 09/25/25
27.69 -5.99%
on 10/03/25
+1.15 (+4.62%)
since 09/05/25
52-Week
20.92 +24.46%
on 04/09/25
27.69 -5.99%
on 10/03/25
+0.33 (+1.28%)
since 12/05/24

Most Recent Stories

More News
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

Findings from the Phase 3 study were presented at the 67 th American Society of Hematology Annual Meeting and Exposition and published in Blood

PFE : 26.03 (+1.28%)
3 Low-Volatility Stocks with Warning Signs

3 Low-Volatility Stocks with Warning Signs

EXPO : 73.22 (-1.39%)
AFL : 109.28 (+0.04%)
PFE : 26.03 (+1.28%)
3 Reasons PFE is Risky and 1 Stock to Buy Instead

3 Reasons PFE is Risky and 1 Stock to Buy Instead

PFE : 26.03 (+1.28%)
U.S. and U.K. Reach Agreement in Principle on Pharmaceutical Pricing in New Economic Prosperity Deal

The United States and the United Kingdom have reached an agreement in principle on pharmaceutical pricing as part of the new U.S.–U.K. Economic Prosperity Deal, aimed at addressing long-standing pricing...

MRK : 99.72 (-1.16%)
PFE : 26.03 (+1.28%)
GSK : 48.41 (-0.33%)
Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:00 a.m. EST on Tuesday, December 16, 2025. The purpose...

PFE : 26.03 (+1.28%)
1 Profitable Stock on Our Buy List and 2 We Turn Down

1 Profitable Stock on Our Buy List and 2 We Turn Down

PAYO : 5.68 (-0.70%)
BCC : 73.05 (-1.63%)
PFE : 26.03 (+1.28%)
4 Unusually Active Options Trades to be Thankful For

As shoppers look to spend over $1 trillion between Black Friday and Christmas, I look back at four unusually active options trades I recommended over the past six weeks. There were good ones and bad ones....

QQQ : 625.48 (+0.41%)
LMND : 78.97 (+2.83%)
STZ : 142.37 (+3.14%)
BBWI : 18.83 (-0.95%)
PFE : 26.03 (+1.28%)
PLTR : 181.76 (+2.16%)
Is Pfizer Stock Underperforming the Dow?

While Pfizer has lagged behind the broader Dow Jones Industrial Average, Wall Street remains optimistic about the stock.

$DOWI : 47,954.99 (+0.22%)
AMGN : 329.89 (-3.02%)
PFE : 26.03 (+1.28%)
Merck & Co. Stock: Is MRK Outperforming the Healthcare Sector?

Merck has outperformed the healthcare sector over the past three months. Moreover, Wall Street analysts are moderately optimistic about its prospects.

XLV : 153.26 (-0.42%)
MRK : 99.72 (-1.16%)
PFE : 26.03 (+1.28%)
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...

ARVN : 12.79 (+1.91%)
PFE : 26.03 (+1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 26.70
2nd Resistance Point 26.41
1st Resistance Point 26.22
Last Price 26.03
1st Support Level 25.74
2nd Support Level 25.45
3rd Support Level 25.26

See More

52-Week High 27.69
Last Price 26.03
Fibonacci 61.8% 25.10
Fibonacci 50% 24.30
Fibonacci 38.2% 23.50
52-Week Low 20.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar